ArticleBreast cancer (Dove Medical Press)2026
Identification of circRNA/lncRNA-miRNA-Transcription Factor-mRNA Networks to Identify Potential Biomarkers in Response to Neoadjuvant Therapy for Breast Cancer.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the Clinical Transformation of circRNA as a Biomarker in Breast Cancer.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant therapy (NAT) is the standard treatment option for locally advanced breast cancer (BC). Noncoding RNAs are known to play a significant role in cancer development. However, the involvement of the circular RNA (circRNA)/long non-coding RNA (lncRNA)-(miRNA)-mRNA competitive endogenous RNA (ceRNA) network in the antitumor effects of NAT in BC remains unclear. Methods: Ribosomal RNA (rRNA)-depleted RNA sequencing (RNA-seq) was performed to identify differentially expressed lncRNAs (DElncRNAs), circRNAs (DEcircRNAs), mRNAs (DEmRNAs) and transcription factors (DE-TFs) between pre-therapy tumor tissues and adjacent normal tissues, as well as between post-NAT tumor tissues and pre-therapy tumor tissues. The changes in gene expression in the ceRNA network were confirmed by RT-qPCR. Results: We identified dysregulated RNAs associated with NAT, including 2693 DEcircRNAs, 25 DElncRNAs, 58 DE-TFs, and 878 DEmRNAs. Three core ceRNA networks were constructed bioinformatically, centered on the key DE-TFs, including HOXC11, NKX2-2, and PRAME. RT-qPCR results confirmed a significant increase in the levels of circRNA_31003, circRNA_42276, MIAT, HOXC11, NKX2-2, PRAME, CCL5, NEK2, and RAD54L in tumor tissues before therapy when compared to normal tissues, but these levels decreased in post-NAT tumor group compared to pre-therapy tumor group. In contrast, the expression of miR-1225-3p, miR-661, and miR-143-5p showed a notable decline in pre-therapy tumors in comparison to normal tissues; however, these expressions elevated significantly in post-NAT tumor group compared to pre-therapy tumor group. Conclusion: Associated regulatory networks were constructed to explore candidate biomarkers that may respond to NAT treatment in BC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.